Co-Authors
This is a "connection" page, showing publications co-authored by Ming-Hua Zheng and Ke-Hua Pan.
Connection Strength
2.001
-
Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Front Endocrinol (Lausanne). 2021; 12:604100.
Score: 0.233
-
Radiomics-based model for accurately distinguishing between severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) and influenza A infected pneumonia. MedComm (2020). 2020 Aug 13.
Score: 0.224
-
Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020 09; 40(9):2160-2163.
Score: 0.223
-
Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021 Jan; 36(1):204-207.
Score: 0.221
-
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 08; 69(8):1545-1547.
Score: 0.221
-
Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care. 2020 Jul; 43(7):e72-e74.
Score: 0.220
-
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol. 2020 09; 73(3):719-721.
Score: 0.220
-
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020 07; 108:154244.
Score: 0.219
-
COVID-19 in a patient with chronic lymphocytic leukaemia. Lancet Haematol. 2020 04; 7(4):e351-e352.
Score: 0.219